Overview
- Within a day of the patent lapse, Dr. Reddy’s, Glenmark and Sun Pharma began Indian sales under the brands Obeda, GLIPIQ, Noveltreat and Sematrinity.
- Reported prices include GLIPIQ at 325–440 rupees per weekly vial, Sun Pharma’s versions at 750–2,000 rupees per week, and Obeda costing about 4,200 rupees per month.
- Company disclosures and reporting indicate price cuts of up to roughly 80% versus Novo Nordisk’s Ozempic and Wegovy.
- India is effectively the first major market with broad generic availability, while Canada lost protection earlier but has not yet approved generics.
- Patents are also expiring in China, Brazil, South Africa, Turkey and Mexico, whereas Argentina’s Dutide is listed near $83 per month compared with some Indian offers near $14.